Non-alcoholic fatty liver disease

3. Emricasan

Conatus’ pan-caspase inhibitor emricasan is one of a pair of drugs for NASH that made it onto our list for 2019, and its failure cost the company a partnership with Novartis that was providing all its revenue and forced it to lay off 40% of its workforce.